Skip to content
  • Contact Us
  • Investors
  • Contact Us
  • Investors
  • About Us
    • Leadership
    • Partnerships
    • Careers
  • Our Science
    • Our Pipeline
    • AMPK activators: SCY-770
    • Antifungal triterpenoids: SCY-247
    • Autosomal Dominant Polycystic Kidney Disease
    • Life-threatening Fungal Infections
    • Publications and Presentations
  • News and Events
    • News
    • Events
  • Careers
  • About Us
    • Leadership
    • Partnerships
    • Careers
  • Our Science
    • Our Pipeline
    • AMPK activators: SCY-770
    • Antifungal triterpenoids: SCY-247
    • Autosomal Dominant Polycystic Kidney Disease
    • Life-threatening Fungal Infections
    • Publications and Presentations
  • News and Events
    • News
    • Events
  • Careers

SCYNEXIS is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases.

Linkedin X-twitter

OUR SCIENCE

|

INVESTORS

|

CORPORATE

Patents

|

Expanded Access

|

Privacy Policy

|

Disclaimer

© 2026 SCYNEXIS, Inc. All Rights Reserved.